Evofem Bioscien Patent-Cliff Exposure & CMS Drug Spending Portfolio

Evofem Bioscien (US): 1 reconciled FDA prescription therapies, $6.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$6.6M
2024 Medicare Part D Spend$82K
2024 Medicaid Spend$6.5M
California HCAI SB 17 Filings1 WAC filings (max 18.4% 2-yr change)